Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Developments Immunology Phase III
Iceland 
Details:
AVT04 (ustekinumab) is a human IgG1k monoclonal antibody that binds with specificity to the p40 protein subunit present in both the IL-12 and IL-23 cytokines.
Lead Product(s): Ustekinumab
Therapeutic Area: Immunology Product Name: AVT04
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
AVT02, a proposed biosimilar to Humira® (adalimumab) inhibits tumor necrosis factor used to treat certain inflammatory conditions. The CHMP’s positive opinion will now be referred to the European Commission for decision to grant a marketing authorization for AVT02.
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: AVT02
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2021
Details:
Under the partnership, Alvotech Hf will be responsible for the development and supply of AVT02, while DKSH will oversee its registration and commercialization.
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: DKSH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 24, 2020
